Yes, not a good appointment for big pharma. |
Closed short at just under 10000pRinse and repeat |
Maybe AZN will be reviewing their planned investment in the US following the nomination of a village idiot as the health secretary? |
'Donald Trump picks Robert Kennedy Jr to run US health department'
Vaccine sceptic and former Democrat latest controversial nomination for cabinet post |
This is uninvestible due to the pekinese situation.Was lucky to have placed a short at 10240 yest |
Look at BRBY this morning in comparison to AZN no wonder the UK market is uninvestable AZM beat expectations and upgraded the share price fell on result day.
Then we have BRBY a large loss today sales falling also huge lease obligations on shops in prime shopping areas and its romping ahead. |
 #POLX Polarean Imaging 1.6p about to break out above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025. 1.6p and gap to fill to 3.2p, so 100% rise just to fill the technical gap. ATH 100p. My target is recovery to 25p.
Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.
Putting this UK recovery play potential on radars.
1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M.
APPROX 13P SHARE PRICE EQUIVALENT FOR POLX
2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M
APPROX 48P SHARE PRICE EQUIVALENT FOR POLX
3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million.
APPROX 22P SHARE PRICE EQUIVALENT FOR POLX
4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout
POLX easy buyout target imv and big riser. DYOR, not advice. |
AstraZeneca backs US and China - but new UK vaccine factory hangs in the balance
Mail Business |
AstraZeneca’s £450m UK investment under review in state aid stand-off
Pharma giant pauses plans for Liverpool factory as it ‘reviews incentives’ |
double post |
Reading the results problems in China seems very low key as below from results looks unlikely that it will cause any lasting problems to AZN, and if it does its only 5% of company profits from which it may lose a few percent not all I would suggest.
As previously disclosed, the Company is aware of a number of individual investigations by the Chinese authorities into current and former AstraZeneca employees. To the best of the Company's knowledge, the investigations include allegations of medical insurance fraud, illegal drug importation and personal information breaches. |
Agree Monty that China is the big hurdle for any positive share price movement regardless of the results and progress they make.
The market hates uncertainty and these are questions that anyone can ask:
What are the repercussions from China ?
Is AZN going to be involved in Chinese courts ?
Possible big fine if breaches are serious ?
Any financial repercussion may hurt AZN numbers thus why the share price is "floating" at the moment.
All these uncertainties will continue to weigh on the share price untill all is clarified once for all. |
These are still looking very weak, I suppose investors hate uncertainty, with China. |
AstraZeneca PLC AstraZeneca invests $3.5 billion in US
MORE THAN A FIRM HANDSHAKE FOR THE INCOMING US PRESIDENT |
They have changed the plans for a cancer drug to target fewer patients which is something the analysts pay a lot of attention to.But I believe it's bigger opportunities are ahead.I have seen in the past that the shares can often be directionless until the US wakes up |
Keep the Faith like Bishop Welby !!
How Low How Soon just like Bishop Welby!! |
Its a disappointingly muted response to excellent figures but as Ijat suggests, its probably as much to do with a general disenchantment with UK equities (and a Labour government that seems confused as to how to promote economic growth)as concern re the China situation.Long term buy but there's a lot more immediate excitement and opportunity on Wall Street PS....i presume that Starmer and Reeves must be disappointed that billions is earmarked for expansion in the USA. |
Shorters were probably prepared to sink it deeper but the results disappointed them.
So any small negative becomes a big issue to justify the drop.
Same things happen in the opposite way for many companies, as usual: Bad results followed by +5% rise. |
While I think the China issues will turn out to be manageable, there is some doublespeak going on…..how many China CEOs are detained without the Company being under investigation……not notified of being investigated is doing the heavy lifting.
I expect a substantial fine and undertakings to do better….in the meantime it is a reason for people to not invest…why would you if you can buy other Pharma without the dark cloud…..however when there is certainty is when the share price can begin to rise.
Those with a 2-3 year time horizon may be well rewarded here by buying in this trough….or you can join the rally when it looks more certain in 12-24months. |
Probably just the UK market at a guess an unbelievable reaction to excellent results. |
Could it be the currency effect that cancelled the positives ? |
Looking very good would never have bought at £130 but at £98 I had to, it seemed far to low for a problem affecting less than 5% of profit. |
Upgrade to full year guidance on the back of some great numbers.Great figures across the board will hopefully ease the China situation and we should have a great day with the share price.Fingers crossed. |
Shore Capital has maintained its ‘buy’ rating on the stock, seeing it as undervalued despite the growing uncertainty. “Q3 results next week could help to allay some of these concerns,” analysts said.
Astrazeneca is due to report its third-quarter results on Tuesday. Investors will be on the lookout for additional product approvals as well as the progress of newly-launched treatments.
Wall Street expects quarterly earnings of $1.01 (78p) per share, an increase of over 16 per cent year over year. Revenue estimates are also up, projected at $13bn (£10bn), annual growth of around 13.5 per cent.
At the half year point, Astrazeneca upgraded its revenue guidance thanks to strong underlying growth in product sales and Alliance Revenue within The company raised its total revenue and core EPS guidance for 2024.
But this “hasn’t been enough to give a further shot in the arm to market sentiment,” said Derren Nathan, head of equity analysis at Hargreaves Lansdown.
“At the third-quarter health check, the market is likely to be paying close attention to the pace of adoption of some core products, and there’s hope that recent approvals will provide a tailwind to growth,” he added.
Overall, analysts reckon the company is on track to hit its $80bn (£62bn) revenue target and a mid-thirties operating margin by 2030.
“Markets aren’t expecting any change to that longer-term steer, but some further reassurance wouldn’t go amiss. The same could be said about some further detail on the investigation by the Chinese authorities into AstraZeneca’s President in the region, Leon Wang,” Nathan said. |
AstraZeneca has explaining to do after £50 billion value wipe out
At the start of September when its share price was at an all-time high
and it was comfortably the UK’s largest company,
AstraZeneca PLC (LSE:AZN) management might have been expecting a routine
third-quarter update.
Two months on however and £50 billion has been wiped from its value
with growing questions over its pipeline and operation in China.
Poor trial results and some questionable PR – putting out a three-
sentence response to the China issue during the middle of Rachel
Reeves’ Budget speech for example - have added to the unease.
The trial disappointments surround its dato-DXd cancer drug and its
fledgling move into the weight loss drug arena.
In China, AstraZeneca has confirmed its president there Leon Wang
is co-operating with the authorities as part of an ongoing investigation
but has given no details, saying it will not comment on speculative media reports.
Some City commentators have suggested that the pharma is not directly
involved and the share price fall is exaggerated.
ShoreCap, in a detailed look at the issue, added Astra could help
alleviate investor concerns by providing clarity on its China business and
reaffirming its growth prospects in the third quarter update.
Whether it chooses to remains to be seen
proactiveinvestors.co.uk |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
